CV Science

William RAOUL PhD, Inserm Researcher CRHC, HDR

Course and current status

Professional experience

Since November 2019: Inserm Researcher CR, Inserm UMR 1069 (Tours, France). Fields : Oncology (Digestive Cancers), Pharmacology, Calcium Signaling, Ion Channels, Lipids, Biomarkers, Innovative Tools

2013-2019 : Inserm Researcher CR, UMR CNRS 7292 (Tours, France). Fields : Therapeutic Monoclonal Antibodies, Oncology (Colorectal Cancer), Pharmacokinetics-Pharmacodynamics, Biomarkers

2012-2013 : Inserm Researcher CR, Inserm UMR S 968, Institut de la Vision (Paris, France). Fields : Age-related macular degeneration, Tools, New Targets

2009-2012: Inserm Researcher CR, Inserm UMR S 872, Centre de Recherche des Cordeliers (Paris, France). Fields : Age-related macular degeneration, Inflammation, Chemokines

2006-2009 : Post-doctoral position, Inserm UMR S 872, Centre de Recherche des Cordeliers (Paris, France). Fields : Age-related macular degeneration, Therapeutics, Angiogenesis

Training

2017 : Habilitation à Diriger des Recherches HDR (authorisation to supervise researches), University François-Rabelais, Tours, France

2001-2005 : PhD in Life and Health Sciences (Toxicology) with honours, Inserm U651, University Paris XII, Créteil, France. Fields : Acute Lung Injury, Pulmonary Arterial Hypertension, Growth Factors, Endothelial Progenitors

2001 : Master in Toxicology with honours, University Paris V Descartes, Paris, France

Scientific summary

The unit has been accredited by Inserm and Tours University for the period 2024-2028 as UMR 1069 N2COx "Niche, Nutrition, Cancer and Oxidative Metabolism". Our research project focused on lipids acting in/on tumor niches, more particularly on energy/oxidative metabolism and calcium Ca2+ signaling, able to influence dysplasia, tumor progression and sensitivity of tumors to anti-cancer drugs. The objective of our bench to bedside research is to facilitate the transfer of fundamental knowledge to patients.

https://fr.linkedin.com/company/inserm-umr1069-n2cox